Hypera plans to introduce a generic version of semaglutide in Brazil following patent expiration in 2026. The company is optimistic about market growth despite potential price impacts. Analysts ...

Scientists are trying to tackle Alzheimer's from all angles, and a new study adds to the growing evidence that semaglutide, a ...

By Alberto Alerigi SAO PAULO (Reuters) -Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

A class action lawsuit was filed against Novo Nordisk A/S (NVO) by Levi & Korsinsky on January 24, 2025. The plaintiffs ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

As China embarks on its three-year "weight management" campaign, Novo Nordisk has stepped forward with its powerful tools to ...

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including new semaglutide ...

Copycat versions of Eli Lilly’s diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They’re ...

Drug compounders are moving to block the FDA’s decision that Novo Nordisk A/S’s weight loss drug is no longer in shortage, ...